Scorpion Therapeutics, Inc.
Funding rounds
3 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jul 2024 | $126 M | No. 3 | $50 to $250 million | equity | SEC | |
| Nov 2020 | $147 M | No. 2 | $50 to $250 million | equity | SEC | |
| Apr 2020 | $25 M | No. 1 | $10 to $50 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Scorpion Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Jul 2024).
SEC Form D · Jul 2024
The industry group it chose in its notices: Biotechnology.
SEC Form D · Jul 2024
That is all the official record says: Scorpion Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services on record: its website does not allow automated readers.
Investors#
4 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Select Biotechnology Portfolio | Fund or asset manager | $4 Mheld | not stated | Holds shares (fund report, May 2026) | SEC Form N-PORT |
| Fidelity Growth Company Fund | Fund or asset manager | $2 Mheld | not stated | Holds shares (fund report, May 2026) | SEC Form N-PORT |
| Fidelity Growth Company K6 Fund | Fund or asset manager | $1 Mheld | not stated | Holds shares (fund report, May 2026) | SEC Form N-PORT |
| Fidelity Series Growth Company Fund | Fund or asset manager | $0 Mheld | not stated | Holds shares (fund report, May 2026) | SEC Form N-PORT |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 38 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Adam Friedman | Executive officer | Jul 2024 |
| Amanda Valentino | Executive officer | Jul 2024 |
| Andrew Fedder | Executive officer | Jul 2024 |
| Brian Piper | Executive officer | Jul 2024 |
| Darrin Stuart | Executive officer | Jul 2024 |
| Erica Jackson | Executive officer | Jul 2024 |
| Mark Chao | Executive officer | Jul 2024 |
| Gary Glick | Executive officer | Dec 2020 |
| Peter Joseph Campisi, Jr. | Executive officer | Dec 2020 |
| Adam Friedman | Director | Jul 2024 |
| Arjun Goyal | Director | Jul 2024 |
| Jean-Francois Formela | Director | Jul 2024 |
| Jeffrey Albers | Director | Jul 2024 |
| Keith Flaherty | Director | Jul 2024 |
| Oleg Nodelman | Director | Jul 2024 |
| Otello Stampacchia | Director | Jul 2024 |
| Saurabh Saha | Director | Jul 2024 |
| Shelley Chu | Director | Jul 2024 |
| Arjun Joseph Goyal | Director | Dec 2020 |
| Gary Glick | Director | Dec 2020 |
| Jean-Francois Joseph Formela | Director | Dec 2020 |
| Keith Joseph Flaherty | Director | Dec 2020 |
| Otello Joseph Stampacchia | Director | Dec 2020 |
| Shelley Joseph Chu | Director | Dec 2020 |
About
Company in Boston, United States.